Kyverna Therapeutics, Inc.
KYTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $7,025 | $5,656 |
| % Growth | – | -100% | 24.2% | – |
| Cost of Goods Sold | $2,133 | $1,707 | $0 | $0 |
| Gross Profit | -$2,133 | -$1,707 | $7,025 | $5,656 |
| % Margin | – | – | 100% | 100% |
| R&D Expenses | $112,473 | $48,216 | $28,402 | $25,852 |
| G&A Expenses | $30,131 | $0 | $8,007 | $6,150 |
| SG&A Expenses | $30,131 | $12,483 | $8,007 | $6,150 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$2,133 | $0 | $0 | $0 |
| Operating Expenses | $140,471 | $60,699 | $36,409 | $32,002 |
| Operating Income | -$142,604 | -$62,406 | -$29,384 | -$26,346 |
| % Margin | – | – | -418.3% | -465.8% |
| Other Income/Exp. Net | $15,127 | $2,040 | $491 | -$4 |
| Pre-Tax Income | -$127,477 | -$60,366 | -$28,893 | -$26,350 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$127,477 | -$60,366 | -$28,893 | -$26,350 |
| % Margin | – | – | -411.3% | -465.9% |
| EPS | -3.33 | -0 | -1.12 | -1.02 |
| % Growth | -3,329,900% | 100% | -9.8% | – |
| EPS Diluted | -3.33 | -0 | -1.12 | -1.02 |
| Weighted Avg Shares Out | 38,335 | 673,622 | 25,804 | 25,804 |
| Weighted Avg Shares Out Dil | 38,335 | 673,622 | 25,804 | 25,804 |
| Supplemental Information | – | – | – | – |
| Interest Income | $15,359 | $2,282 | $565 | $1 |
| Interest Expense | $142 | $187 | $65 | $3 |
| Depreciation & Amortization | $2,133 | $1,707 | $1,051 | $586 |
| EBITDA | -$125,202 | -$58,472 | -$27,777 | -$25,761 |
| % Margin | – | – | -395.4% | -455.5% |